BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33876668)

  • 1. Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer.
    Jiang W; He Z; Zhang T; Guo C; Zhao J; Zhu J; Wu J; Yu X; Chen C; Li J; Jiang J
    Immunotherapy; 2021 Jun; 13(8):661-668. PubMed ID: 33876668
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
    Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G
    J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
    Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Sondhi M; Wang Y; Chakravartty A; Rodriguez-Lorenc K; Taran T; Jerusalem G
    N Engl J Med; 2020 Feb; 382(6):514-524. PubMed ID: 31826360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
    Wan X; Zhang Y; Ma J; Tan C; Zeng X; Peng L
    Breast; 2019 Feb; 43():1-6. PubMed ID: 30342258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Huang X; Lin S; Rao X; Zeng D; Wang H; Weng X; Huang P
    Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
    Fasching PA; Beck JT; Chan A; De Laurentiis M; Esteva FJ; Jerusalem G; Neven P; Pivot X; Bianchi GV; Martin M; Chandiwana D; Lanoue B; Ridolfi A; Wang Y; Rodriguez Lorenc K; Nusch A
    Breast; 2020 Dec; 54():148-154. PubMed ID: 33065342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K; Burum A; Jeong E; Zhong L
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
    Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
    Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
    Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
    J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
    Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
    Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.